In the E-3193 trial, 345 premenopausal patients with low-risk breast cancer (node-negative, hormone receptor-positive, tumour size ≤ 3 cm) were randomized to receive tamoxifen alone or tamoxifen plus OFS. This evidence concerns the gene NR4A1 and breast carcinoma.